GB Sciences Sponsors "Innovation in Medical Cannabis Therapies" Symposium

GBS Life Sciences is currently working with research scientists in seven locations to discover disease-modifying compounds that occur naturally in the cannabis plant and has organized this symposium to gather more like-minded innovators who will create both novel cannabis-based medicines to help the many patients who need therapeutic options, as well as the tech and biotech tools to manufacture and develop those plant-based medicines.

"GB Sciences is committed to promoting innovation in the creation of cannabis therapies, but we know that we cannot do it alone," said John Poss, CEO and Chairman of GB Sciences; "Supporting programs like this is our way of encouraging others to join us and to ride this wave of innovation. True cooperation by like-minded people is the only way that this industry can move forward in a positive direction."

To sign up for the Innovation Conference or for further information visit the https://gbsciences.com/innovation-symposium

About GB Sciences, Inc.

GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control.  It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov.  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Note:  Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.

Contact Information

Corporate:

GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118
866-721-0297, or 
Tom Arcuragi, EVP, tom@gbsciences.com

View original content with multimedia:http://www.prnewswire.com/news-releases/gb-sciences-sponsors-innovation-in-medical-cannabis-therapies-symposium-300614591.html

SOURCE GB Sciences, Inc.